Duvic M, Cather J, Maize J, Frankel A E
Department of Dermatology, MD Anderson Cancer Center, Houston, Texas, USA.
Am J Hematol. 1998 May;58(1):87-90. doi: 10.1002/(sici)1096-8652(199805)58:1<87::aid-ajh18>3.0.co;2-2.
Four patients with late stage cutaneous T cell lymphoma (IB-IVA) who had failed at least two previous therapies were treated with DAB389IL2 at 9 or 18 microg/kg as 15-min intravenous infusions daily for 5 days every 3 weeks for eight cycles. Mild vascular leak syndrome (VLS) with transient edema, hypoalbuminemia, weight gain, and myalgias was observed in two of the patients lasting 7-10 days and only occurring on the first cycle. One stage IB patient had a pathologic complete remission (CR) lasting 11+ months from treatment initiation, one stage IIB patient had a complete clinical remission (CCR) lasting >6 months with complete clearing of a large tumor lasting >18 months, and one stage IIB and the one stage IVA patient had partial remissions (80-99% reduction in tumor masses) lasting 5 months. While IL2 receptor (IL2R) was expressed on 20-50% of tumor cells prior to therapy, recurrent tumor was IL2R negative in three of the patients. DAB389IL2 at tolerable doses decreased tumor burden in each of these four standard treatment refractory CTCL patients and may offer an important alternative to standard palliative chemotherapy regimens.
4例晚期皮肤T细胞淋巴瘤（IB-IVA期）患者，既往至少两种治疗失败，接受DAB389IL2治疗，剂量为9或18μg/kg，静脉输注15分钟，每天1次，共5天，每3周重复，共8个周期。2例患者出现轻度血管渗漏综合征（VLS），伴有短暂性水肿、低白蛋白血症、体重增加和肌痛，持续7-10天，仅在第1周期出现。1例IB期患者自治疗开始后病理完全缓解（CR）持续11个多月，1例IIB期患者临床完全缓解（CCR）持续>6个月，大肿瘤完全消退持续>18个月，1例IIB期和1例IVA期患者部分缓解（肿瘤肿块缩小80-99%）持续5个月。治疗前20-50%的肿瘤细胞表达白细胞介素2受体（IL2R），3例患者复发肿瘤为IL2R阴性。可耐受剂量的DAB389IL2降低了这4例标准治疗难治性CTCL患者的肿瘤负荷，可能为标准姑息化疗方案提供重要替代方案。
